Last reviewed · How we verify
mRNA-1283.815
mRNA-1283.815 is a messenger RNA-based vaccine that encodes for a specific protein to stimulate an immune response.
mRNA-1283.815 is a messenger RNA-based vaccine that encodes for a specific protein to stimulate an immune response. Used for COVID-19.
At a glance
| Generic name | mRNA-1283.815 |
|---|---|
| Sponsor | ModernaTX, Inc. |
| Drug class | mRNA vaccine |
| Modality | Biologic |
| Therapeutic area | Infectious disease |
| Phase | Phase 3 |
Mechanism of action
This vaccine works by introducing a piece of genetic material called messenger RNA into cells, which then produces the protein that the immune system recognizes as foreign and mounts a response against. This response can help the body fight off infections or diseases caused by the protein.
Approved indications
- COVID-19
Common side effects
- Pain, redness, or swelling at the injection site
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- mRNA-1283.815 CI brief — competitive landscape report
- mRNA-1283.815 updates RSS · CI watch RSS
- ModernaTX, Inc. portfolio CI